Less than one year after CytRx announced that it had spun out its RNAi therapeutics assets into RXi Pharmaceuticals, the new company has registered with US regulators those of its shares that will be distributed to CytRx shareholders and employees — one of the last steps toward establishing RXi as an independent company.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.